Fennec Pharmaceuticals Inc
F:RV41
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fennec Pharmaceuticals Inc
F:RV41
|
US |
|
Ecovyst Inc
NYSE:ECVT
|
US |
|
F
|
FirstEnergy Corp
SWB:FE7
|
US |
|
K
|
Komatsu Ltd
XMUN:KOM1
|
JP |
|
Sinopec Oilfield Service Corp
OTC:YZCFF
|
CN |
|
Fairfax Financial Holdings Ltd
TSX:FFH
|
CA |
|
S
|
Silvercorp Metals Inc
F:S9Y
|
CA |
|
F
|
Fennec Pharmaceuticals Inc
SWB:RV41
|
US |
|
S
|
Sirius XM Holdings Inc
DUS:RDO
|
US |
|
Y
|
Yamana Gold Inc
LSE:AUY
|
CA |
|
C
|
Chow Tai Fook Jewellery Group Ltd
XBER:1CT
|
HK |
|
Simulations Plus Inc
NASDAQ:SLP
|
US |
|
D
|
Deutsche Post AG
XHAM:DPW
|
DE |
|
F
|
Fuji Media Holdings Inc
F:FTN
|
JP |
|
Airtel Africa PLC
LSE:AAF
|
UK |
Wall St Price Targets
RV41 Price Targets Summary
Fennec Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RV41 is 13.51 EUR with a low forecast of 11.17 EUR and a high forecast of 16.08 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RV41's stock price target?
Price Target
13.51
EUR
According to Wall Street analysts, the average 1-year price target for RV41 is 13.51 EUR with a low forecast of 11.17 EUR and a high forecast of 16.08 EUR.
What is the Revenue forecast for Fennec Pharmaceuticals Inc?
Projected CAGR
48%
The compound annual growth rate for Revenue over the next 3 years is 48%.
What is the Gross Profit forecast for Fennec Pharmaceuticals Inc?
Projected CAGR
46%
The compound annual growth rate for Gross Profit over the next 3 years is 46%.
